Cell Free Protein Expression Market – Insights
Cell free protein expression is also called as cell-free protein synthesis, in vitro translation, cell-free translation or in vitro protein expression. It is a well-developed, rapid, and efficient technique for synthesizing proteins in cell lysates rather than cultured cells. Cell free protein expression uses translation machineries to extract the desired cells. It can be done by using various types of mammalian cells, bacteria, plants, and insect cells over conventional in vivo method. For instance, cell free protein expression system works independently and is free of any cellular context, owing to these benefits it is ideal for high-throughput screening of mutagenesis. Moreover, the whole machinery of cell free expression system sets better environment to manufacture membrane proteins, toxic proteins, and proteins that can undergo degradation. Pharmaceutical and biotechnological industries actively utilize these tools for research and developmental activities as well as for genomics and proteomics. Thus, it is a key factor propelling the cell free protein expression market growth over the forecast period.
The global cell free protein expression market sizewas valued at US$ 177.1 million in 2017, and is expected to witness a CAGR of 6.2% over the forecast period (2018 – 2026).
Global Cell Free Protein Expression Market, By End User (Share Analysis (%)), 2017
Source: Coherent Market Insights Analysis (2018)
Robust research and development is expected to drive growth of the cell free protein expression market
Increasing research and development in the field of proteomics and genomics and high prevalence of infectious disease and cancer are the major factors driving growth of the cell free protein expression market. For instance, According to 2012, EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world. Moreover, high prevalence of infectious disease and cancer cases across the world are resulting into high adoption of cell samples for research and development of drugs thus, expected to have a meteoric growth for the cell free protein expression market. For instance, According to the estimates by GLOBOCAN 2012, an estimated 850,000 new cancer cases were diagnosed in Africa, while almost 600,000 deaths were attributed to malignant disease. The number of cancer cases is expected to rise to 1,056,000 by 2020. Furthermore, According to the World Health Organization (WHO), in 2012, around 3,319 deaths occurred due to the infectious and parasitic disease infection, in Sub Saharan Africa region and according to the same source, in 2014, Ebola accounted for around 8,000 deaths in this region.
However, high cost, low yield of protein from certain species, lack of eukaryotic co- and post-translational modifications may hamper the growth of the market. For instance, cell free system based on E.coli and wheat germ extracts have some limitation to produce human proteins with post translation modifications (PTMs), which is restraining growth of the cell free protein expression market growth.
For In depth Information Get Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/1082
Cell Free Protein Expression Market- Regional Analysis
Cell free protein expression market is segmented into six major regions- North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Increasing cell-based research in North America due to high demand for precision medicine is a major factor driving growth of the cell free protein expression market in this region. In 2015, the Precision Medicine Initiative was launched in the U.S. to revolutionize the treatment of diseases, which include cancer and other chronic diseases, as precision medicine offers tailored treatment for an individual according to genetic makeup of the person. Furthermore, increasing emphasis on proteomics and genomics research activities in UK, Germany, France, and Switzerland are fueling growth of the European cell free protein expression market. For instance, in 2018, UK Biobank is taking initiative to sequence the full genomes of 50,000 UK Biobank volunteer participants. This initiative is funded £30M (US$ 39.8 Mn) grant from the Medical Research Council (MRC). This investment has accelerates research activities for wide range of diseases associated with disability and premature death in mid to later life. The Asia Pacific is estimated to witness significant growth in cell free protein expression market, owing to increasing number of research laboratories, contract research organizations and pharmaceutical companies with increased expenditure on research and development. For instance, China’s expenditure on research and development increased by 11.6% year-on-year to US$ 280 Bn in 2017.
Cell Free Protein Expression Market- Competitive Landscape
Increasing investments and initiatives by various manufacturers supports growth of the cell free protein expression market over the forecast period. For instance, in September 2017, iBio, Inc. with its subsidiary iBio CDMO LLC, a contract development and manufacturing organization (CDMO) collaborated with TheoremDx, Inc. to develop proteins for rapid diagnostic testing products. The collaboration aims to offer plant proteins through robust development and manufacturing in the U.S. and other economies. IBio is expected to provide an expression system to TheoremDx, which allows establishment of new diagnostics through cGMP scale-up production. Both iBio and TheoremDx are specifically focusing on development of rapid diagnostic tests, which can help in identifying and distinguishing neglected tropical diseases such as Zika, West Nile, Dengue, and Chikungunya. This collaboration is a major strategic step for advancement of rapid detection test internationally.
Key players operating in cell free protein expression market include iBio CDMO LLC, Thermo Fisher Scientific Inc., Takara Bio, Inc., New England Biolabs, Promega Corporation, CellFree Sciences Co., Ltd., Biotechrabbit GmbH, Bioneer Corporation, Cube Biotech GmbH, Jena Bioscience GmbH, and GeneCopoeia, Inc.